• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Prenetics Global Limited (Amendment)

    7/25/23 12:34:59 PM ET
    $PRE
    Blank Checks
    Finance
    Get the next $PRE alert in real time by email
    SC 13D/A 1 d511914dsc13da.htm SCHEDULE 13D AMENDMENT NO. 2 SCHEDULE 13D AMENDMENT NO. 2

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Prenetics Global Limited

    (Name of Issuer)

    Class A ordinary shares, US$0.0001 par value per share

    (Title of Class of Securities)

    G72245106

    (CUSIP Number)

    Da Yeung Limited

    Yeung Danny Sheng Wu

    Unit 701-706, K11 Atelier King’s Road

    728 King’s Road, Quarry Bay

    Hong Kong

    Tel: +852-2210-9588

    July 20, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    This statement on Schedule 13D constitutes Amendment No. 2 to the initial Schedule 13D (the “Original Schedule 13D”) filed on May 31, 2022 on behalf of each of Da Yeung Limited and Yeung Danny Sheng Wu, with respect to ordinary shares (“Ordinary Shares”), comprising Class A ordinary shares, par value US$0.0001 per share (“Class A Ordinary Shares”), and Class B ordinary shares, par value US$0.0001 per share (“Class B Ordinary Shares”), of Prenetics Global Limited (the “Issuer”), an exempted company limited by shares incorporated under the laws of the Cayman Island.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


        SCHEDULE 13D    Page 2 of 6

    CUSIP No. G72245106

     

      (1)    

      Names of reporting persons

     

      Da Yeung Limited

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      ☐  (a) ☐  (b)

     

      (3)  

      SEC use only

     

      (4)  

      Source of funds (see instructions)

     

      OO

      (5)  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      (6)  

      Citizenship or place or organization

     

      British Virgin Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

     

         (7)     

      Sole voting power

     

      9,713,864(1)

         (8)   

      Shared voting power

     

         (9)   

      Sole dispositive power

     

      9,713,864(1)

       (10)   

      Shared dispositive power

     

    (11)    

      Aggregate amount beneficially owned by each reporting person

     

      9,713,864(1)

    (12)  

      Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    (13)  

      Percent of class represented by amount in Row (11)

     

      5.39%(2)

    (14)  

      Type of reporting person (see instructions)

     

      CO

     

    (1)

    Represents 9,713,864 Class B Ordinary Shares directly held by Da Yeung Limited, a British Virgin Islands company wholly owned by Yeung Danny Sheng Wu. Each Class B Ordinary Share is convertible at the option of the holder into one Class A Ordinary Share. Class A Ordinary Shares are not convertible into Class B Ordinary Shares under any circumstances. The rights of the holders of Class A Ordinary Shares and Class B Ordinary Shares are identical, except with respect to conversion rights (noted above) and voting rights. Each Class B Ordinary Share is entitled to twenty (20) votes, whereas each Class A Ordinary Share is entitled to one vote.

    (2)

    Calculated based on 180,271,908 Ordinary Shares as a single class (being the sum of 157,674,687 Class A Ordinary Shares and 22,597,221 Class B Ordinary Shares) to which this report is related, issued and outstanding as of July 20, 2023. The Class B Ordinary Shares are treated as converted into Class A Ordinary Shares only for the purpose of calculating the percentage of ownership of the Reporting Person.


        SCHEDULE 13D    Page 3 of 6

    CUSIP No. G72245106

     

      (1)    

      Names of reporting persons

     

      Yeung Danny Sheng Wu

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      ☐  (a) ☐  (b)

     

      (3)  

      SEC use only

     

      (4)  

      Source of funds (see instructions)

     

      OO

      (5)  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      (6)  

      Citizenship or place or organization

     

      Hong Kong SAR

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

     

         (7)     

      Sole voting power

     

      22,597,221(1)

         (8)   

      Shared voting power

     

         (9)   

      Sole dispositive power

     

      22,597,221(1)

       (10)   

      Shared dispositive power

     

    (11)    

      Aggregate amount beneficially owned by each reporting person

     

      22,597,221(1)

    (12)  

      Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    (13)  

      Percent of class represented by amount in Row (11)

     

      12.54%(2)

    (14)  

      Type of reporting person (see instructions)

     

      IN

     

    (1)

    Represents (i) 12,883,357 Class B Ordinary Shares directly held by Yeung Danny Sheng Wu, and (ii) 9,713,864 Class B Ordinary Shares held by Da Yeung Limited, a British Virgin Islands company wholly owned by Yeung Danny Sheng Wu. Each Class B Ordinary Share is convertible at the option of the holder into one Class A Ordinary Share. Class A Ordinary Shares are not convertible into Class B Ordinary Shares under any circumstances. The rights of the holders of Class A Ordinary Shares and Class B Ordinary Shares are identical, except with respect to conversion rights (noted above) and voting rights. Each Class B Ordinary Share is entitled to twenty (20) votes, whereas each Class A Ordinary Share is entitled to one vote.

    (2)

    Calculated based on 180,271,908 Ordinary Shares as a single class (being the sum of 157,674,687 Class A Ordinary Shares and 22,597,221 Class B Ordinary Shares) to which this report is related, issued and outstanding as of July 20, 2023, assuming conversion of all Class B Ordinary Shares into Class A Ordinary Shares. The Class B Ordinary Shares are treated as converted into Class A Ordinary Shares only for the purpose of calculating the percentage of ownership of the Reporting Person.


     

    AMENDMENT NO. 2 TO

    SCHEDULE 13D

       Page 4 of 6

     

    Pursuant to Rule 13d-2 promulgated under the Act, this Amendment No. 2 (this “Amendment No. 2”), amends and supplements the previously filed Schedules 13D filed by Da Yeung Limited and Yeung Danny Sheng Wu. Except as otherwise set forth herein, this Amendment No. 2 does not modify any of the information in the previously filed Schedules 13D. Capitalized terms used in this Amendment No. 2 and not otherwise defined herein shall have the same meanings ascribed to them in the previously filed Schedules 13D.

    Item 5. Interest in Securities of the Issuer.

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    (a) and (b): The responses of each Reporting Person to Rows (7) through (13) of the cover pages of this Schedule 13D are hereby incorporated by reference in this Item 5.

    The percentage of the class of securities identified pursuant to Item 1 beneficially owned by the Reporting Person is based on a total of 180,271,908 issued and outstanding Ordinary Shares (consisting of 157,674,687 Class A Ordinary Shares and 22,597,221 Class B Ordinary Shares) of the Issuer as of July 20, 2023. Each Class B Ordinary Share is convertible at the option of the holder into one Class A Ordinary Share. Class A Ordinary Shares are not convertible into Class B Ordinary Shares under any circumstances. The rights of the holders of Class A Ordinary Shares and Class B Ordinary Shares are identical, except with respect to conversion rights (noted above) and voting rights. Each Class B Ordinary Share is entitled to twenty (20) votes, whereas each Class A Ordinary Share is entitled to one vote.

    The shares beneficially owned by Da Yeung Limited represent approximately 5.39% of the total issued and outstanding ordinary shares of the Issuer and represent approximately 31.87% of the aggregate voting power of the Issuer’s total issued and outstanding ordinary shares.

    The shares beneficially owned by Yeung Danny Sheng Wu represent approximately 12.54% of the total issued and outstanding ordinary shares of the Issuer and represent approximately 74.14% of the aggregate voting power of the Issuer’s total issued and outstanding ordinary shares.

    (c): None of the Reporting Persons have effected any transaction in the Ordinary Shares during the past 60 days. However, due to the issuance of 22,222,222 Class A Ordinary Shares pursuant to share sale agreement entered into between the Issuer and certain parties on 25 June 2023 for the acquisition of an equity stake in Insighta Holdings Limited, the total number of issued and outstanding Ordinary Shares increased from a total of 158,049,686 to 180,271,908 on July 20, 2023, resulting in the reduction in the percentage of issued and outstanding ordinary shares of the Issuer held by each Reporting Person as shown in Row (13) of the cover pages of this Schedule 13D.

    (d): None.

    (e): Not applicable.


        SCHEDULE 13D    Page 5 of 6

     

    Item 7. Materials to be Filed as Exhibits.

    Item 7 of the Original Schedule 13D is hereby amended and restated as follows:

     

    Exhibit

    No.

      

    Description

    A    Joint Filing Agreement dated May  31, 2022 by and between the Reporting Persons (previously filed with the SEC as Exhibit A to the Original Schedule 13D filed by the Reporting Persons on May 31, 2022).
    B    Registration Rights Agreement, dated as of September  15, 2021, by and among Prenetics Global Limited, Artisan Acquisition Corp., Artisan LLC, Danny Sheng Wu Yeung and other parties named therein (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form F-1 (File No. 333-265284) filed with the SEC on May 27, 2022).
    C    Shareholder Support Agreements and Deed, dated as of September  15, 2021, by and among Prenetics Global Limited, Prenetics Group Limited, Artisan Acquisition Corp., and certain management shareholders named therein (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form F-1 (File No. 333-265284) filed with the SEC on May 27, 2022).
    D    Amendment to Shareholder Support Agreement, dated as of March  30, 2022, by and among Prenetics Global Limited, Prenetics Group Limited, Artisan Acquisition Corp. and certain management shareholders named therein (incorporated by reference to Exhibit 10.23 to the Registration Statement on Form F-1 (File No. 333-265284) filed with the SEC on May 27, 2022).
    E    Prenetics Global Limited 2022 Share Incentive Plan (incorporated herein by reference to Exhibit 4.4 to the Form 20-F transition report filed with the SEC on May 27, 2022)
    F    Share sale agreement dated as of 25  June 2023, by and among Prenetics Global Limited, Lo Yuk Ming Dennis and Chan Kwan Chee (incorporated by reference to Exhibit 10.23 to the Registration Statement on Form  F-1 (File No. 333-265284) filed with the SEC on July 6, 2023)


    Signatures

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

           Yeung Danny Sheng Wu
    Date: July 25, 2023    Signature:   

    /s/ Yeung Danny Sheng Wu

       Name:    Yeung Danny Sheng Wu

     

           Da Yeung Limited
    Date: July 25, 2023    Signature:   

    /s/ Yeung Danny Sheng Wu

       Name:    Yeung Danny Sheng Wu
       Title:    Director
    Get the next $PRE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRE

    DatePrice TargetRatingAnalyst
    1/18/2023$7.00Overweight
    Cantor Fitzgerald
    7/12/2022Buy
    Citigroup
    More analyst ratings

    $PRE
    Leadership Updates

    Live Leadership Updates

    See more
    • Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors

      LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company's Board of Directors. "We are excited to welcome Kathryn and David to Prenetics' Board of Directors at this pivotal juncture," said Danny Yeung, CEO of Prenetics. "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." "I am thrilled to join Prenetics at such a p

      7/1/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station

      (From left: Dr. Ghada Alsaleh, Sonia Pawelczyk, Danny Yeung, Dr. James L. Green, Ahmed Alfandi, Dr. Tara Ruttley, Wasim Ahmed, Dr. Hilde Stenuit, Dr. Camille Alleyne at the MOU signing ceremony in Dubai, UAE Space Agency) Initial research project is with NDORMS, Botnar Research Institute, University of Oxford, focusing on accelerated aging in spaceDr. James L. Green, former Chief Scientist of NASA and Dr. Tara Ruttley, former Associate Chief Scientist of NASA to join Prenetics Scientific Advisory BoardInaugural research cube scheduled to be sent on-board SpaceX to the ISS in Q4 of 2024 DUBAI, United Arab Emirates, Feb. 09, 2024 (GLOBE NEWSWIRE) -- UAE Space Agency – Prenetics Global Li

      2/9/24 9:25:22 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    SEC Filings

    See more
    • SEC Form S-8 filed by Prenetics Global Limited

      S-8 - Prenetics Global Ltd (0001876431) (Filer)

      5/7/25 8:47:19 AM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form 20-F filed by Prenetics Global Limited

      20-F - Prenetics Global Ltd (0001876431) (Filer)

      4/30/25 4:44:18 PM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form 6-K filed by Prenetics Global Limited

      6-K - Prenetics Global Ltd (0001876431) (Filer)

      3/5/25 8:34:06 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Financials

    Live finance-specific insights

    See more
    • Prenetics Announces Third Quarter 2024 Financial Results

      Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Invests $30 million in Insighta's Early Cancer Detection Reiterates Revenue Target to Exceed $33 million for FY 2024 CHARLOTTE, N.C., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the third quarter ended September 30, 2024, along with recent business updates. Third Quarter 2024 Financial Highlights Revenue from continuing operations of $7.8 million, as compared to $4.9 million in the thi

      11/27/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces Second Quarter 2024 Financial Results

      Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024Enters U.S. Health Market in October with IM8, a New Health and Wellness BrandRe-affirms Revenue Target to Exceed US$33 million for FY 2024 CHARLOTTE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the second quarter ended June 30, 2024, along with recent business updates. Second Quarter 2024 Financial Highlights Revenue from continuing operations of US$5.9 million, as compared to US$6.5 million in the second quarter 2023 attributable to clinical segment revenues, which are anticipa

      10/7/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces Acquisition of Europa Sports Partners in Strategic Expansion to Consumer Health and Wellness Industry

      Europa Is One of the Largest Sports Nutrition Distributors With a Network of 10,000+ Gyms Across the United States Supports Prenetics' New Health and Wellness Brand IM8 with David Beckham as its Co-Founding Partner Projected Revenue of $100 Million+ in Consumer Segment for FY2025 CHARLOTTE, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, is pleased to announce the acquisition of Europa Sports Partners ("Europa") and subsidiary, Hubmatrix, a global ecommerce and retail logistics provider. This strategic acquisition marks a significant milestone in Prenetics' expansion into the $1

      8/19/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $PRE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cantor Fitzgerald initiated coverage on Prenetics Group Ltd. with a new price target

      Cantor Fitzgerald initiated coverage of Prenetics Group Ltd. with a rating of Overweight and set a new price target of $7.00

      1/18/23 7:56:45 AM ET
      $PRE
      Blank Checks
      Finance
    • Citigroup initiated coverage on Prenetics Group Ltd.

      Citigroup initiated coverage of Prenetics Group Ltd. with a rating of Buy

      7/12/22 11:48:35 AM ET
      $PRE
      Blank Checks
      Finance
    • IM8 Vibrante Miami: Fueling Wellness and Innovation with a Star-Studded Event

      David Beckham was Joined by Dr. Amy Shah, Dr. Jeremy London, Dr. James DiNicolantonio and Kendal Toole to Reinforce IM8's Vision for Elite Wellness Accessible to All CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- On Monday, IM8, the premium supplement brand co-founded by David Beckham, hosted IM8 Vibrante - A Celebration of Science, Wellness & Flavor, a memorable evening at the iconic Faena Theater on Miami Beach. In attendance were nearly 150 wellness influencers, creators, science and medical advisors, and media members to celebrate the brand's ongoing commitment to transforming the status quo of wellness by blending innovation in science and medicine while prioritizing holistic he

      4/9/25 9:00:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics' IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market

      Adds Renowned Clinical Experts Dr. Jeremy London and Dr. Amy Shah to Existing Team from Mayo Clinic, Cedars-Sinai, NASA and Yale University CHARLOTTE, N.C., March 18, 2025 (GLOBE NEWSWIRE) --  IM8, the premium supplements brand co-founded by David Beckham, today announced the addition of two distinguished new members, Dr. Jeremy London and Dr. Amy Shah, to its world-class Scientific Advisory Board (SAB). These additions underscore IM8's unwavering commitment to leading innovation in science, longevity and human performance. Newly joining IM8's SAB are: Dr. Amy Shah – An acclaimed integrative medicine physician and double board-certified expert in Internal Medicine, Dr. Shah focuses on g

      3/18/25 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics to Participate in the 37th Annual ROTH Conference

      CHARLOTTE, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading consumer health sciences company, announced today the Company will participate in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA. Prenetics' Chief Executive Officer Danny Yeung and President of Americas David Vanderveen will be available to host one-on-one meetings with investors during the event. In addition, management will participate in a panel discussion on Longevity and Supplementation on Monday, March 17th at 12:00pm PT. Interested parties may access the panel through the webcast link here w

      3/11/25 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Prenetics Global Limited

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      11/14/24 12:30:15 PM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      2/5/24 6:05:14 AM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      11/27/23 6:05:43 AM ET
      $PRE
      Blank Checks
      Finance